Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia

References

• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Al Hamad M. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review. F1000Res. 2021;10:1288. doi:10.12688/f1000research.74570.1
   PubMedGoogle Scholar
• Igelmann S, Neubauer HA, Ferbeyre G. STAT3 and STAT5 activation in solid cancers. Cancers. 2019;11(10):1428. doi:10.3390/cancers11101428
   PubMed Web of Science ®Google Scholar
• Larrue C, Heydt Q, Saland E, et al. Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. Oncogenesis. 2019;8(8):39. doi:10.1038/s41389-019-0148-9
   PubMedGoogle Scholar
• Wingelhofer B, Maurer B, Heyes EC, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;32(5):1135–1146. doi:10.1038/s41375-017-0005-9
   PubMed Web of Science ®Google Scholar
• Dumas PY, Naudin C, Martin-Lanneree S, et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL. Haematologica. 2019;104(10):2017–2027. doi:10.3324/haematol.2018.205385
   PubMed Web of Science ®Google Scholar
• Minieri V, De Dominici M, Porazzi P, et al. Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia. Cancer Res. 2018;78(20):5793–5807. doi:10.1158/0008-5472.CAN-18-0195
   PubMed Web of Science ®Google Scholar
• Katerndahl CDS, Heltemes-Harris LM, Willette MJL, et al. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol. 2017;18(6):694–704. doi:10.1038/ni.3716
   PubMed Web of Science ®Google Scholar
• Klein K, Witalisz-Siepracka A, Maurer B, et al. STAT5B (N642H) drives transformation of NKT cells: a novel mouse model for CD56(+) T-LGL leukemia. Leukemia. 2019;33(9):2336–2340. doi:10.1038/s41375-019-0471-3
   PubMed Web of Science ®Google Scholar
• Mi T, Wang Z, Bunting KD. The cooperative relationship between STAT5 and reactive oxygen species in leukemia: mechanism and therapeutic potential. Cancers. 2018;10(10.
   PubMed Web of Science ®Google Scholar
• Brachet-Botineau M, Polomski M, Neubauer HA, et al. Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers. Cancers. 2020;12(1):240. doi:10.3390/cancers12010240
   PubMed Web of Science ®Google Scholar
• Nelson EA, Sharma SV, Settleman J, et al. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget. 2011;2(6):518–524. doi:10.18632/oncotarget.296
   PubMedGoogle Scholar
• Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421–3429. doi:10.1182/blood-2009-11-255232
   PubMed Web of Science ®Google Scholar
• Liu HM, Guo CL, Zhang YF, et al. Leonurine-repressed miR-18a-5p/SOCS5/JAK2/STAT3 axis activity disrupts CML malignancy. Front Pharmacol. 2021;12:657724. doi:10.3389/fphar.2021.657724
   PubMed Web of Science ®Google Scholar
• Cui P, Wei F, Hou J, et al. STAT3 inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction. Cell Signal. 2020;71:109598. doi:10.1016/j.cellsig.2020.109598
   PubMed Web of Science ®Google Scholar
• Linher-Melville K, Nashed MG, Ungard RG, et al. Chronic inhibition of STAT3/STAT5 in treatment-resistant human breast cancer cell subtypes: convergence on the ROS/SUMO pathway and its effects on xCT expression and system xc- activity. PloS one. 2016;11(8):e0161202. doi:10.1371/journal.pone.0161202
   PubMed Web of Science ®Google Scholar
• Hindupur SV, Schmid SC, Koch JA, et al. STAT3/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy. Int J Mol Sci. 2020;21(3):1106. doi:10.3390/ijms21031106
   PubMed Web of Science ®Google Scholar
• Shao D, Ma J, Zhou C, et al. STAT3 down-regulation induces mitochondria-dependent G2/M cell cycle arrest and apoptosis in oesophageal carcinoma cells. Clin Exp Pharmacol Physiol. 2017;44(3):413–420. doi:10.1111/1440-1681.12708
   PubMed Web of Science ®Google Scholar
• Tsujita Y, Horiguchi A, Tasaki S, et al. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells. Oncol Rep. 2017;38(4):2197–2204. doi:10.3892/or.2017.5902
   PubMed Web of Science ®Google Scholar
• Haftchenary S, Luchman HA, Jouk AO, et al. Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma. ACS Med Chem Lett. 2013;4(11):1102–1107. doi:10.1021/ml4003138
   PubMed Web of Science ®Google Scholar
• Warsch W, Grundschober E, Berger A, et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget. 2012;3(12):1669–1687. doi:10.18632/oncotarget.806
   PubMedGoogle Scholar
• Cheng Y, Hao Y, Zhang A, et al. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib. Int J Mol Med. 2018;41(1):455–463.
   PubMed Web of Science ®Google Scholar
• Warsch W, Grundschober E, Sexl V. Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle. 2013;12(12):1813–1814. doi:10.4161/cc.25116
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang X, Liu Y, et al. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-kappaB signaling and reversal by Wogonin. Oncotarget. 2016;7(17):24436–24454. doi:10.18632/oncotarget.8332
   PubMedGoogle Scholar
• Zhao M, Yang C, Chai S, et al. Curcumol and FTY720 synergistically induce apoptosis and differentiation in chronic myelomonocytic leukemia via multiple signaling pathways. Phytotherapy Research: PTR. 2021;35(4):2157–2170. doi:10.1002/ptr.6968
   PubMed Web of Science ®Google Scholar
• Cheng L, Tang Y, Chen X, et al. Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells. Cancer Biol Ther. 2018;19(8):676–686. doi:10.1080/15384047.2018.1450113
   PubMed Web of Science ®Google Scholar
• Stella S, Tirro E, Conte E, et al. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Mol Cancer Ther. 2013;12(6):1085–1098. doi:10.1158/1535-7163.MCT-12-0550
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Schneeweiss M, Eisenwort G, et al. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017;102(9):1519–1529. doi:10.3324/haematol.2016.163436
   PubMed Web of Science ®Google Scholar
• Memarzadeh K, Savage DJ, Bean AJ. Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition. Cancer Biol Ther. 2019;20(12):1416–1429. doi:10.1080/15384047.2019.1647049
   PubMed Web of Science ®Google Scholar
• Zhao C, Li H, Lin HJ, et al. Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci. 2016;37(1):47–61. doi:10.1016/j.tips.2015.10.001
   PubMed Web of Science ®Google Scholar
• Zhou X, Ren Y, Liu A, et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Sci Rep. 2014;4:7461.
   PubMed Web of Science ®Google Scholar
• Casetti L, Martin-Lanneree S, Najjar I, et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res. 2013;73(7):2052–2058. doi:10.1158/0008-5472.CAN-12-3955
   PubMed Web of Science ®Google Scholar
• Prost S, Relouzat F, Spentchian M, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature. 2015;525(7569):380–383. doi:10.1038/nature15248
   PubMed Web of Science ®Google Scholar